---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-136730"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:36:49.264774+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed

## Summary
- Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.
- Cash $14.1M at Mar 31; subsequent $40M oversubscribed PIPE closed Apr 22 extends runway through 2025.
- First OPMD subject showed clinically meaningful improvements in swallowing at 90 days post BB-301 dose; no SAEs.
- Second subject dosed safely; third expected June 2024; 23 subjects enrolled in natural history study.
- Additional interim safety/efficacy data expected H2 2024; Suvretta Capital led PIPE.

## SEC filing metadata
- accession: 0001193125-24-136730
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/0001193125-24-136730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/d792227d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-136730
- JSON: https://secwatch.observer/filing/0001193125-24-136730.json
- Plain text: https://secwatch.observer/filing/0001193125-24-136730.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2024 results: revenue $0.
  - Period: third fiscal quarter ended March 31, 2024
  - Revenue: $0
  - Result: reported results
  source text: Total Revenues for the quarter ended March 31, 2024, were $0 compared to $54,000 in licensing revenues collected for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/0001193125-24-136730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.